A Phase I Study on Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) for the Treatment of Advanced Malignant Solid Tumors

Advanced Solid Tumor Clinical Trial

— MIZAR-001  

Official title:

An Open, Single-armed, Phase I Study to Evaluate the Safety and Efficacy Using Autologous TIL in Patients With Advanced Malignant Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05417750
• Other study ID #: GC101 TIL-ST-01
• Status: Recruiting
• Phase: Phase 1
• Start date: July 30, 2022
• Est. completion date: April 30, 2025

Study information

• Verified date: April 2024
• Source: Shanghai Juncell Therapeutics
• Contact: Mengmeng Tang
• Phone: 86-021-69110327
• Email: clinicaltrials[@]juncell.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

20-60 participants are expected to be enrolled for the Phase I clinical trial which is further divided into two parts: a "3+3" dose escalation study and an expanded enrollment study.

The Phase I clinical trial is expected to be finished in 36 months. To be specific, the dose escalation study plans to include patients with advanced malignant solid tumors with clear pathological diagnosis, including melanoma, cervical cancer, head and neck squamous cell tumors, non-small cell lung cancer and breast cancer, etc.; while the expanded enrollment study plans to include those with melanoma, cervical cancer, and head and neck squamous cell tumors.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: April 30, 2025
• Est. primary completion date: November 7, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Patients must be =18 and =75 years of age at the time of consent.

2. Patients with advanced metastatic solid tumors with clear pathological diagnosis, including melanoma, cervical cancer, head and neck squamous cell tumors, non-small cell lung cancer and breast cancer, etc.; while the expanded enrollment study plans to include those with melanoma, cervical cancer, and head and neck squamous cell tumors.

3. At least one measurable target lesion even after resection, as defined by RECIST1.1.

Lesions in previously irradiated areas (or other local therapy) should not be selected as target lesions, unless treatments was =3 months prior to Screening, and there has been demonstrated disease progression in that particular lesion.

4. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

5. Patients must have an estimated life expectancy of =3 months.

6. In the opinion of the Investigator, patients must be able to sign the ICF and complete all study-required procedures.

7. Patients must have the following hematologic parameters, Coagulation functions and hepatic and renal function:

• White Blood Cell (WBC)=2.5×10^9/L;

• Absolute Lymphocyte Count (ANC)=1.5×10^9/L;

• Absolute Lymphocyte Count(ALC)=0.7×10^9/L;

• Platelet=100×10^9/L;

• International Normalized Ratio(INR)=1.5×ULN;

• Activated Partial Thromboplastin Time(APTT)=1.5×ULN;

• Serum Creatinine (Scr)=1.5mg/dL (or 132.6µmol/L) or Creatinine Clearance=60mL/min

• Urinalysis: urine protein less than 2+, or 24-hour urine protein <1g;

• Alanine aminotransferase(AST/SGOT) =3×ULN;

• Alanine aminotransferase (ALT/SGPT) =3×ULN;

• Total Bilirubin(TBIL)=1.5×ULN;

8. Patients must have a washout period = 4 weeks from prior anticancer therapy(ies) to the start of the planned preconditioning regimen, including targeted therapy, chemotherapy, immunotherapy: anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)/anti-PD-1, other monoclonal antibody (mAb), or vaccine Palliative radiation therapy.

9. Patients of childbearing potential or their partners of childbearing potential must be willing to take the appropriate precaution to avoid pregnancy or fathering a child for the duration of the study and practice an approved, highly effective method of birth control during treatment and for 12 months after receiving the last protocol-related therapy.

10. Patients must have no contraindications for surgery or biopsy.

11. Patients (or legally authorized representative) must have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an ICF approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC), and agree to abide by the study restrictions and return to the site for the required assessments, including the OS Follow-up Period.

Exclusion Criteria:

1. Patients have not recovered from all prior therapy-related adverse events (AEs) to = Grade 1 (per Common Terminology Criteria for Adverse Events [CTCAE] v5.0), except for alopecia or vitiligo, prior to Enrollment (tumor resection).

2. Patients who have received an organ allograft or prior cell transfer therapy.

3. Patients with symptomatic and/or untreated brain metastases (of any size and any number).

4. Patients who are on chronic systemic steroid therapy for any reason.

5. Patients who have active medical illness(es) that would pose increased risk for study participation, including: active systemic infections requiring systemic ABX, coagulation disorders, or other active major medical illnesses of the cardiovascular, respiratory, or immune system.

6. Patients with systemic active infection requiring treatment, with positive blood culture or imaging evidence of infection, including active tuberculosis.

7. Patients with hepatic encephalopathy, hepatorenal syndrome, Child-Pugh class B or more severe cirrhosis, or liver failure.

8. Uncontrolled arterial hypertension(SBP=160mmHg and/or DBP=100mmHg)or any unstable cardiovascular or cerebrovascular disease in the recent 6 months of consent.

9. Patients who have a left ventricular ejection fraction (LVEF) < 50% or New York Heart Association (NYHA) functional classification Class 3 or Class 4.

10. Female patients who are pregnant or breastfeeding.

11. Patients who are HIV positive, positive syphilis serological test, positive COVID-19 nucleic acid test, or clinically active hepatitis A, B, and C including virus carriers.

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Adverse Drug Event
• Drug-Related Side Effects and Adverse Reactions
• Efficacy
• Immunotherapy
• Neoplasms
• Safety

Intervention

Drug:
• TIL therapy
A tumor sample is resected from each participant and cultured ex vivo to expand the population of autologous tumor infiltrating lymphocytes injection (GC101 TIL). After lymphodepletion, patients are infused GC101 TIL followed sintilimab.

Locations

Country	Name	City	State
China	Chinese PLA General Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Juncell Therapeutics

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximal Tolerance Dose		Up to Day 28
Primary	Dose Limiting Toxicity		Up to Day 28
Primary	Adverse Events		Maximum 360 days
Secondary	Disease Assessment for Duration of Response	Evaluate the efficacy endpoints of DOR by the investigator with RECIST v1.1 and iRECIST	Every 6 weeks for 12 months
Secondary	Disease Assessment for Disease Control Rate	Evaluate the efficacy endpoints of DCR by the investigator with RECIST v1.1 and iRECIST	Every 6 weeks for 12 months
Secondary	Disease Assessment for Progression-Free Survival	Evaluate the efficacy endpoints of PFS by the investigator with RECIST v1.1 and iRECIST	Every 6 weeks for 12 months
Secondary	Disease Assessment for Objective Response Rate	Evaluate the efficacy endpoints of ORR by the investigator with RECIST v1.1 and iRECIST	Every 6 weeks for 12 months
Secondary	Quality of Life Assessment	Evaluate with EORTC QLQ-C30	Every 6 weeks for 12 months